

Giuseppe M C Rosano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9107235/publications.pdf>

Version: 2024-02-01

59
papers

25,284
citations

156536

32
h-index

139680

61
g-index

62
all docs

62
docs citations

62
times ranked

28847
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of heart failure: a comprehensive and updated review of epidemiology. <i>Cardiovascular Research</i> , 2023, 118, 3272-3287.	1.8	517
2	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	1.4	5
3	From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 83-85.	1.4	1
4	Sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e9-e10.	1.4	0
5	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	6
6	New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e89-e90.	1.4	2
7	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1844-1854.	2.9	42
8	Survival to intensive care unit discharge among in-hospital cardiac arrest patients by applying audiovisual feedback device. <i>ESC Heart Failure</i> , 2021, , .	1.4	2
9	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692.	0.8	15
10	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 97-103.	1.4	14
11	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
12	Inter-twinned relationship between heart failure and atrial fibrillation. <i>Heart</i> , 2020, 106, 1125-1126.	1.2	6
13	2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 331-332.	1.4	3
14	Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. <i>Cardiac Failure Review</i> , 2020, 6, e31.	1.2	17
15	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 306-317.	1.9	125
16	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 745-754.	0.4	4
17	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
18	Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-15.	1.9	237

#	ARTICLE	IF	CITATIONS
19	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
20	Under-representation of elderly and women in clinical trials. <i>International Journal of Cardiology</i> , 2017, 232, 216-221.	0.8	105
21	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	1.0	40
22	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , 2017, 19, 449-456.	2.9	19
23	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients with Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2885-2896.	1.2	198
24	Incretin-based therapy for type 2 diabetes: A real class effect?. <i>International Journal of Cardiology</i> , 2017, 227, 141-142.	0.8	2
25	The mitochondrial metabolic reprogramming agent trimetazidine as an "exercise mimetic"™ in cachectic C26-bearing mice. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 954-973.	2.9	63
26	Heart Failure in Patients with Diabetes Mellitus. <i>Cardiac Failure Review</i> , 2017, 03, 52.	1.2	122
27	Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumor-bearing c26 mice. <i>Oncotarget</i> , 2017, 8, 113938-113956.	0.8	29
28	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2016, 220, 595-601.	0.8	59
29	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
30	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	2.9	455
31	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
32	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
33	Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 449-457.	2.9	44
34	Clinical Trial Design, Endpoints, and Regulatory Requirements. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 67-78.	0.9	5
35	Effect of age and sex on efficacy and tolerability of β^2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016, 353, i1855.	3.0	95
36	Animal models of cardiac cachexia. <i>International Journal of Cardiology</i> , 2016, 219, 105-110.	0.8	27

#	ARTICLE	IF	CITATIONS
37	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 909-915.	0.8	67
38	Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 37-38.	1.4	2
39	Adaptive licensing "A way forward in the approval process of new therapeutic agents in Europe. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2015, 1, 1-2.	1.0	1
40	Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 197-204.	1.2	25
41	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.	1.7	13
42	Adaptive licensing "A way forward in the approval process of new therapeutic agents in Europe. <i>International Journal of Cardiology</i> , 2015, 184, 568-569.	0.8	3
43	Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.	2.9	11
44	Apaf1-deficient cortical neurons exhibit defects in axonal outgrowth. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4173-4191.	2.4	7
45	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 331-339.	1.0	4
46	Disclosure of negative trial results. A call for action. <i>International Journal of Cardiology</i> , 2015, 198, 47-48.	0.8	8
47	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 181, 239-244.	0.8	88
48	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
49	Exercise-Induced Skeletal Muscle Remodeling and Metabolic Adaptation: Redox Signaling and Role of Autophagy. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 154-176.	2.5	157
50	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	1.2	34
51	Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. <i>International Journal of Cardiology</i> , 2013, 163, 320-325.	0.8	77
52	Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. <i>Heart Failure Clinics</i> , 2013, 9, 285-290.	1.0	37
53	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
54	The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. <i>FEBS Journal</i> , 2013, 280, 5094-5108.	2.2	39

#	ARTICLE	IF	CITATIONS
55	A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. <i>American Heart Journal</i> , 2012, 163, 1019-1023.	1.2	41
56	Trimetazidine improves exercise performance in patients with peripheral arterial disease. <i>Pharmacological Research</i> , 2011, 63, 278-283.	3.1	37
57	Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. <i>Advances in Therapy</i> , 2009, 26, 455-461.	1.3	31
58	The Metabolic Syndrome in Women. <i>Women's Health</i> , 2006, 2, 889-898.	0.7	5
59	Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. <i>Cardiovascular Diabetology</i> , 2003, 2, 16.	2.7	111